UK - AstraZeneca has injected £100m into its UK pension scheme.
The Anglo-Swedish pharmaceutical group’s £2bn pension scheme now has a 95% FRS17 funding level.
The AstraZeneca Pension Fund closed its defined benefit scheme to new members in 2002 and has started a defined contribution scheme.
The scheme reported an FRS17 deficit of £323m following the decline in the stock market over the last three years.
Finance director Jon Symonds said there would be no further need to top up the fund after the latest injection.
Nick Martindale looks at how Leeds-based digital marketing agency Search Laboratory has taken significant steps to improve mental health wellbeing
The publication of DC to DC transfer time performance data sets a benchmark for trust-based schemes. Jonathan Stapleton reports.
The Cost Transparency Initiative (CTI) has set out plans to launch the long-awaited cost disclosure templates for pension schemes in mid-May.
This week's top stories included Smart Pension and Moore Stephens master trusts being fined for historic chair's statement failures.